Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Dave Marek
PharmaShots Interview: Myovant’s Dave Marek Shares Insights on the US FDA’s Approval of Myfembree in Uterine Fibroids
In an interview with PharmaShots, Dave Marek. CEO of Myovant shares insights on the US FDA's approval of Myfembree (relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg) in Uterine Fibroids. Shots: The US FDA has approved Myovant & Pfizer's Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as the first once-daily treatment for the…
July 20, 2021
Viewpoints_Mark Wildgust, Paolo Ghia & Paul Barr
PharmaShots Interview: Janssen’s Mark Wildgust along with Two Other Key Speakers Share Insights on Data Presented at ASCO 2021
In an interview with PharmaShots, Mark Wildgust, VP of Global Medical Affairs, Oncology at Janssen, Dr. Paolo Ghia, Division of Experimental Oncology at Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele and Paul Barr, Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute at University of Rochester…
July 19, 2021
Viewpoints_Denis Corin
PharmaShots Interview: Q BioMed’s Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs
In an interview with PharmaShots, Denis Corin, Chief Executive Officer and Chairman of the Board at Q BioMed share his views on the supply agreement for Strontium89 with the US Department of Defense and Veterans Affairs. Shots: BioMed has signed a 5-year agreement to commercially serve the US Department of Veterans Affairs (VA) and Department of Defense…
July 13, 2021
Viewpoints_Dr. Ramon Mohanlal
PharmaShots Interview: BeyondSpring’s Dr. Ramon Mohanlal Shares Insights on the Data of Triple Combo Plinabulin Presented at ASCO 2021
In an interview with PharmaShots, Ramon Mohanlal, M.D., Ph.D., MBA, Chief Medical Officer and Executive Vice President of Research and Development at BeyondSpring share his views on the data of triple combination regimen presented at ASCO and also shed light on the impact of plinabulin on SCLC. Shots: Plinabulin in combination with nivolumab and ipilimumab showed 46% ORR with one…
July 12, 2021
Viewpoints_Dr. Minnie Sarwal
PharmaShots Interview: NephroSant’s Dr. Minnie Sarwal Shares Insights on QSant and the Need for Precision Medicine in Kidney Health
In an interview with PharmaShots, Dr. Minnie Sarwal, CEO and Co-Founder of NephroSant shares her view on the QSant and how this urine test can improve outcomes for transplant patients. She also shed light on the need for precision therapies in kidney transplant care. Shots: NephroSant's Qsant is a needle-free urine test that helps in determining if…
July 7, 2021
Viewpoints_Dr. Jan Wehkamp and Dr. Bruce Sands
PharmaShots Interview: Janssen’s Dr. Jan Wehkamp and Icahn School of Medicine’s Dr. Bruce Sands Share Insights on the Data Presented at DDW 2021
In an interview with PharmaShots, Dr. Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader at Janssen, and Bruce Sands, Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine share their views on the data of Stelara and Tremfya presented at DDW 2021. Shots: Janssen presented the new data on Stelara (ustekinumab) and…
July 2, 2021
Viewpoints_Nathalie Landry
PharmaShots Interview: Medicago’s Nathalie Landry Shares Insights on the Phase 2 Results of Plant-Based COVID-19 Vaccine
In an Interview with PharmaShots, Nathalie Landry, Executive Vice President, Scientific, and Medical Affairs at Medicago share her views on the P-II results of adjuvanted plant-based COVID-19 vaccine. Shots: The P-II study involves assessing the safety & immunogenicity of the CoVLP vs PBO in 306 subjects aged =18yrs. with two age groups (18-64yrs & over 65yrs.) across…
June 29, 2021
Viewpoints_Kevin Cammack
PharmaShots Interview: Eli Lilly’s Kevin Cammack Shares Insights on Lilly’s Collaboration with Global Diabetes Technology Companies
In an interview with PharmaShots, Kevin Cammack, Head of Connected Care, Eli Lilly and Company shares insights on the Lilly alliance with DexCom, Glooko, myDiabby Healthcare, and Roche to provide compatibility between their unique digital management platforms and Lilly's Tempo Pen and Tempo Smart Button. Shots: Eli Lilly collaborates with DexCom, Glooko, myDiabby Healthcare, and Roche to…
June 28, 2021
Load more